Assenagon Asset Management S.A. Sells 76,026 Shares of Outset Medical, Inc. (NASDAQ:OM)

Assenagon Asset Management S.A. lowered its holdings in shares of Outset Medical, Inc. (NASDAQ:OMFree Report) by 7.4% in the 1st quarter, Holdings Channel.com reports. The fund owned 944,845 shares of the company’s stock after selling 76,026 shares during the period. Assenagon Asset Management S.A.’s holdings in Outset Medical were worth $2,098,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of OM. Mubadala Investment Co PJSC bought a new position in shares of Outset Medical during the fourth quarter valued at $7,794,000. PFM Health Sciences LP bought a new position in shares of Outset Medical during the fourth quarter valued at $5,406,000. Braidwell LP increased its position in shares of Outset Medical by 64.4% during the third quarter. Braidwell LP now owns 2,400,427 shares of the company’s stock worth $26,117,000 after buying an additional 940,059 shares during the period. GSA Capital Partners LLP increased its position in shares of Outset Medical by 508.9% during the fourth quarter. GSA Capital Partners LLP now owns 514,317 shares of the company’s stock worth $2,782,000 after buying an additional 429,851 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Outset Medical by 38.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 706,969 shares of the company’s stock worth $7,692,000 after buying an additional 197,082 shares during the period.

Outset Medical Stock Performance

NASDAQ:OM traded up $0.07 during trading hours on Tuesday, reaching $3.68. The company had a trading volume of 817,471 shares, compared to its average volume of 1,203,542. The company has a current ratio of 6.42, a quick ratio of 5.32 and a debt-to-equity ratio of 2.11. The business’s 50-day simple moving average is $2.57 and its two-hundred day simple moving average is $3.76. Outset Medical, Inc. has a twelve month low of $1.92 and a twelve month high of $24.13.

Outset Medical (NASDAQ:OMGet Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.03). The company had revenue of $30.51 million during the quarter, compared to analyst estimates of $30.40 million. Outset Medical had a negative return on equity of 120.67% and a negative net margin of 134.93%. On average, equities analysts predict that Outset Medical, Inc. will post -2.23 EPS for the current fiscal year.

Insider Activity

In other news, CTO Jean-Olivier Racine sold 8,306 shares of Outset Medical stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $3.27, for a total transaction of $27,160.62. Following the completion of the transaction, the chief technology officer now directly owns 265,325 shares in the company, valued at $867,612.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 23,921 shares of company stock worth $78,934 over the last three months. 3.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

OM has been the subject of several recent analyst reports. CL King upgraded shares of Outset Medical from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research report on Friday, April 5th. BTIG Research initiated coverage on shares of Outset Medical in a research report on Monday, April 8th. They set a “buy” rating and a $6.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Outset Medical has a consensus rating of “Hold” and a consensus price target of $5.42.

View Our Latest Analysis on Outset Medical

Outset Medical Profile

(Free Report)

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.

See Also

Want to see what other hedge funds are holding OM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Outset Medical, Inc. (NASDAQ:OMFree Report).

Institutional Ownership by Quarter for Outset Medical (NASDAQ:OM)

Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.